Oregovomab
Oregovomab is a monoclonal antibody used in the treatment of ovarian cancer. It targets the antigen CA-125, which is often elevated in ovarian cancer patients. Oregovomab is designed to stimulate the patient's immune system to recognize and attack cancer cells expressing CA-125.
Mechanism of Action[edit | edit source]
Oregovomab binds to the CA-125 antigen, which is present on the surface of ovarian cancer cells. This binding event is thought to activate the immune system, particularly T-cells, which then learn to recognize and kill cells expressing CA-125. This approach is part of a broader category of cancer therapy known as immunotherapy, which aims to boost the body's own immune system to fight cancer.
Clinical Trials[edit | edit source]
Oregovomab has been evaluated in several clinical trials. Early phase trials focused on assessing its safety and optimal dosing strategies. Subsequent trials have evaluated its efficacy, often comparing it with standard chemotherapy treatments or in combination with other therapeutic agents. The results of these trials have been mixed, with some showing promise in extending survival or delaying disease progression, while others have not demonstrated significant benefits.
Usage[edit | edit source]
The use of oregovomab is typically considered in cases of advanced ovarian cancer where traditional therapies have failed or as part of a clinical trial setting. Its administration involves intravenous infusions, and the treatment regimen can vary depending on the specific clinical trial or treatment protocol.
Side Effects[edit | edit source]
As with many cancer treatments, oregovomab can cause side effects. These may include flu-like symptoms such as fever, chills, and fatigue, which are common to treatments that stimulate the immune system. More severe immune-related adverse effects can also occur, although they are less common.
Current Status[edit | edit source]
As of the last update, oregovomab is not widely used outside of clinical trials. Research is ongoing to better understand its potential role in ovarian cancer treatment, including its use in combination with other therapies.
See Also[edit | edit source]
 | This medical article is a stub. You can help WikiMD by expanding it. |
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
